ARRY presents excellent updated CRC data at WorldGI2018

Congrats Array Biopharma on continued excellent data on its colorectal cancer (CRC) study of patients with BRAF V600E mutations with the triple therapy - Cetuximab, Array's BRAF inhibitor Bini and Array's BRAF inhibitor Enco. Overall survival not reached at 12.6 months vs. historical overall survival in this population of less than 8 months, and 48% ORR (3 CRs) vs. 16% ORR with competitive VIC therapy. Image shows best patient tumor measurements in this triplet vs. historical treatment (inset). Looking forward to PDUFA decisions on ARRY Bini and Enco in melanoma in coming days.

#colorectal #CRC #ARRY #targetedtherapies #ArrayBiopharma #AmpFree

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon